Sign in Subscribe
Cancer research

Anaplastic Thyroid Cancer Pipeline Outlook 2025

Strategic Insights

— 2 min read

The Anaplastic Thyroid Cancer pipeline report provides insights into the latest therapies and clinical trials for the treatment of Anaplastic Thyroid Cancer. The report reveals that there are 8+ active players working on 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment. The leading companies in the Anaplastic Thyroid Cancer pipeline space include Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.

Key Takeaways:

  • In August 2025, University of Arizona announced a Phase I study to examine the safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens, with a main cohort of N=20-24 patients with extracranial anatomic radiation sites.
  • DelveInsight's Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working on 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
  • The leading companies in the Anaplastic Thyroid Cancer pipeline space include Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb, and others.
  • Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208, and others.
  • Sapanisertib, a dual TORC 1/2 inhibitor developed by Takeda, has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC).
  • HLX208, a BRAF V600E small-molecule inhibitor developed by Shanghai Henlius Biotech, can be potentially used in the treatment of various solid tumors.
  • DelveInsight's Anaplastic Thyroid Cancer Pipeline report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same.
  • The report accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment.
  • Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

Statistics:

  • 8+ active players are working on 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment.
  • The Anaplastic Thyroid Cancer pipeline report includes 8+ pipeline drugs for Anaplastic Thyroid Cancer treatment.
  • Takeda has the largest number of pipeline drugs for Anaplastic Thyroid Cancer treatment with 5+ pipeline drugs.
  • Shanghai Henlius Biotech has 3+ pipeline drugs for Anaplastic Thyroid Cancer treatment.
  • AffyImmune Therapeutics, Inc. has 2+ pipeline drugs for Anaplastic Thyroid Cancer treatment.

Sources:

  • DelveInsight's, "Anaplastic Thyroid Cancer Pipeline Insight 2025" report
  • University of Arizona
  • M2 PressWIRE-August 20, 2025-: Anaplastic Thyroid Cancer Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies (C)1994-2025 M2 COMMUNICATIONS RDATE:19082025

Read more